We carried out micro-array phosphatome profiling in 41 estrogen receptor-negative (ER−) BC patients, as determined by immunohistochemistry (IHC), containing both ERBB2+ and ERBB2− in order to characterize the differences between these two groups. This evidence concerns the gene ERBB2 and breast cancer.